Benefits of ADHD Treatment in Detained People

• Status: Not yet recruiting
• Trial end date: 2026-10-30
• Target enrollment: 0
• Participant gender: Male

Summary

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stéphanie Baggio
• Collaborators: Netherlands Institute for the Study of Crime; School of Health Sciences Fribourg; University of Geneva, Switzerland; University of Lausanne
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• age between 18 and 65

• good command of French

• going to be released in approx. 4 months at eligibility visit

• endorsing clinical diagnostic criteria for DSM-5 ADHD

• providing written informed consent

Exclusion Criteria:

• presence of an acute uncontrolled comorbid psychiatric disorder

• going in a closed centre after release from prison

• medical contraindication to stimulant prescription

• potential adverse interaction with another medication

• already receive ADHD treatment

• do not plan to stay in Switzerland for at least one year.